XOMA Co. (NASDAQ: XOMA) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% [Yahoo! Finance]
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
XOMA Co. (NASDAQ: XOMA) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $40.00 price target on the stock.